Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Three European Countries Using 28-Month Overall Survival from Checkmate 067
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.197
https://www.valueinhealthjournal.com/article/S1098-3015(17)30531-4/fulltext
Section Title :
Disease-Specific Studies
Section Order :
177
First Page :
A432
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30531-4&doi=10.1016/j.jval.2017.08.197